We are developing transformative therapies to treat repeat expansion and other severe genetic disorders at their source. Learn more about our clinical programs and studies.

Triplet Development Pipeline

Pipeline 8-18-21

TTX-3360, an antisense oligonucleotide, is Triplet’s first clinical candidate. TTX-3360 is the first clinical candidate with the potential to modify the course of REDs, including HD, by targeting the DDR pathway. Triplet plans to file an investigation new drug application or equivalent in mid-2022, with a focus on HD. TTX-3360 may also be a candidate for the treatment of other central nervous system diseases including SCAs, DM1 and approximately 30 additional potential REDs impacting the central nervous system.